FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to experimental cardiac pharmacology and can be used for endothelial dysfunction correction. The method of endothelial dysfunction correction is declared.
EFFECT: invention provides activation of endothelial dysfunction correction in experimental reactive vasculitis.
1 cl, 1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CORRECTING ENDOTHELIAL DYSFUNCTION WITH AZITHROMYCIN IN MODELING OF CHRONIC GRAM-POSITIVE SEPSIS | 2009 |
|
RU2400826C1 |
| METHOD FOR EVALUATION OF ENDOTHELIAL DYSFUNCTION IN CASE OF EXPERIMENTAL REACTIVE VASCULITIS | 2009 |
|
RU2405413C1 |
| MIDECAMYCIN-BASED CORRECTION MODE OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | 2007 |
|
RU2353370C1 |
| JOSAMYCIN THERAPY FOR ENDOTHELIUM DYSFUNCTION CORRECTION ASSOCIATED WITH L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | 2007 |
|
RU2353369C1 |
| METHOD FOR COMBINED TADALAFIL AND L-NORVALINE CORRECTION OF L-NAME INDUCED NITROGEN OXIDE DEFICIENCY IN EXPERIMENT | 2012 |
|
RU2500040C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF INDAPAMIDE AND L-ARGININE IN L-NAME-INDUCED NITROGEN DEFICIT | 2005 |
|
RU2306929C1 |
| METHOD FOR RESTRICTING NECROSIS AREA AT MODELING CORONAROOCCLUSION MYOCARDIAL INFARCTION IN ANIMALS AT DECREASED ANTIOXIDANT BACKGROUND | 2002 |
|
RU2226101C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF ENALAPRIL AND RESVERATROL IN L-NAME-INDUCED DEFICIENCY OF NITROGEN OXIDE | 2005 |
|
RU2301670C1 |
| METHOD FOR RESTRICTING THE NECROSIS AREA WITH CLARITROMYCIN WHILE MODELING CORONARY OCCLUSION MYOCARDIAL INFARCTION IN ANIMALS | 2006 |
|
RU2318507C1 |
| METHOD FOR RESTRICTING THE NECROSIS AREA WITH ROXYTROMYCIN WHILE MODELING CORONARY OCCLUSION MYOCARDIAL INFARCTION IN ANIMALS | 2006 |
|
RU2318506C1 |
